Press & Media Coverage
Catch up on our latest press coverage
Imagion initiates leadership restructuring plan
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
Quarterly Activity Report and Appendix 4C for 31 March 2023
https://youtu.be/8MSNhYapsRI Highlights: Reported positive results of independent review of utility for MagSense® HER2 breast cancer detection Announced plan to advance MagSense® HER2 program to multi-site
Notice of 2022 Annual General Meeting and Proxy Form
In accordance with Listing Rule 3.17, Imagion Biosystems Limited attaches a copy of the following documents: 1. Letter to Shareholders regarding arrangements for the Annual
[Infographic] MagSense® Imaging Agent Technology Overview
Imagion Biosystems (ASX:IBX) is a biotech company dedicated to improving healthcare through the earlier detection of cancer and other diseases. We are using our proprietary
April 2023 Investor Newsletter
We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April
Pitt Street Research Conducts Market Research Report on Imagion – April 2023
Pitt Street Research has published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.